Breakthrough Therapy (BT) Designation Market Size, Share, Trends, Growth and Forecast 2032

Breakthrough Therapy (BT) Designation Market

Breakthrough Therapy (BT) Designation Market - By Application (Oncology, Rare Diseases, Infectious Diseases, Pulmonary Diseases, Autoimmune Diseases, Neurological Disorders, Others), And By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2024 - 2032

Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-2939 Published Date: Oct-2024 Status : Published
Market Size in 2023 Market Forecast in 2032 CAGR (in %) Base Year
USD 130.78 Billion USD 529.08 Billion 16.8% 2023

Breakthrough Therapy (BT) Designation Market

Request For Customization Request Free Sample Buy Now

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Breakthrough Therapy (BT) Designation Market , 2015–2025 (USD Billion)
    • 2.2. Breakthrough Therapy (BT) Designation Market : Snapshot
  • Chapter 3. Global Breakthrough Therapy (BT) Designation Market – Industry Analysis
    • 3.1. Breakthrough Therapy (BT) Designation Market : Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Inflating consumption of orphan medicines and large-scale acceptance of BT status in drugs will embellish the market expansion over the years ahead.
      • 3.2.2. Surge in the healthcare spending in both emerging economies and developed countries will prompt the market size over the forecast timeline.
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Application
  • Chapter 4. Global Breakthrough Therapy (BT) Designation Market – Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Breakthrough Therapy (BT) Designation Market : company market share, 2017
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Breakthrough Therapy (BT) Designation Market – Application Analysis
    • 5.1. Global Breakthrough Therapy (BT) Designation Market overview: By Application
      • 5.1.1. Global Breakthrough Therapy (BT) Designation Market share, By Application, 2018 and 2025
    • 5.2. Onculogy
      • 5.2.1. Global Breakthrough Therapy (BT) Designation Market By Onculogy, 2015–2025 (USD Billion)
    • 5.3. Rare Diseases
      • 5.3.1. Global Breakthrough Therapy (BT) Designation Market By Rare Diseases, 2015–2025 (USD Billion)
    • 5.4. Infectious Diseases
      • 5.4.1. Global Breakthrough Therapy (BT) Designation Market By Infectious Diseases, 2015–2025 (USD Billion)
    • 5.5. Pulmonary Diseases
      • 5.5.1. Global Breakthrough Therapy (BT) Designation Market By Pulmonary Diseases, 2015–2025 (USD Billion)
    • 5.6. Autoimmune Diseases
      • 5.6.1. Global Breakthrough Therapy (BT) Designation Market By Autoimmune Diseases, 2015–2025 (USD Billion)
    • 5.7. Neurulogical Disorders
      • 5.7.1. Global Breakthrough Therapy (BT) Designation Market By Neurulogical Disorders, 2015–2025 (USD Billion)
    • 5.8. Others
      • 5.8.1. Global Breakthrough Therapy (BT) Designation Market By Others, 2015–2025 (USD Billion)
  • Chapter 6. Company Profiles
    • 6.1. Regeneron
      • 6.1.1. Overview
      • 6.1.2. Financials
      • 6.1.3. Product Portfolio
      • 6.1.4. Business Strategy
      • 6.1.5. Recent Developments
    • 6.2. GlaxoSmithKline plc
      • 6.2.1. Overview
      • 6.2.2. Financials
      • 6.2.3. Product Portfolio
      • 6.2.4. Business Strategy
      • 6.2.5. Recent Developments
    • 6.3. Bristul-Myers Squibb Company
      • 6.3.1. Overview
      • 6.3.2. Financials
      • 6.3.3. Product Portfolio
      • 6.3.4. Business Strategy
      • 6.3.5. Recent Developments
    • 6.4. Acadia Pharmaceuticals, Inc.
      • 6.4.1. Overview
      • 6.4.2. Financials
      • 6.4.3. Product Portfolio
      • 6.4.4. Business Strategy
      • 6.4.5. Recent Developments
    • 6.5. Pfizer, Inc.
      • 6.5.1. Overview
      • 6.5.2. Financials
      • 6.5.3. Product Portfolio
      • 6.5.4. Business Strategy
      • 6.5.5. Recent Development
    • 6.6. Novartis AG
      • 6.6.1. Overview
      • 6.6.2. Financials
      • 6.6.3. Product Portfolio
      • 6.6.4. Business Strategy
      • 6.6.5. Recent Development
    • 6.7. AbbVie, Inc.
      • 6.7.1. Overview
      • 6.7.2. Financials
      • 6.7.3. Product Portfolio
      • 6.7.4. Business Strategy
      • 6.7.5. Recent Development
    • 6.8. AstraZeneca
      • 6.8.1. Overview
      • 6.8.2. Financials
      • 6.8.3. Product Portfolio
      • 6.8.4. Business Strategy
      • 6.8.5. Recent Development
    • 6.9. Gilead
      • 6.9.1. Overview
      • 6.9.2. Financials
      • 6.9.3. Product Portfolio
      • 6.9.4. Business Strategy
      • 6.9.5. Recent Development
    • 6.10. Janssen Global Services, LLC
      • 6.10.1. Overview
      • 6.10.2. Financials
      • 6.10.3. Product Portfolio
      • 6.10.4. Business Strategy
      • 6.10.5. Recent Development
    • 6.11. F. Hoffmann-La Roche Ltd
      • 6.11.1. Overview
      • 6.11.2. Financials
      • 6.11.3. Product Portfolio
      • 6.11.4. Business Strategy
      • 6.11.5. Recent Development
    • 6.12. Amgen, Inc.
      • 6.12.1. Overview
      • 6.12.2. Financials
      • 6.12.3. Product Portfolio
      • 6.12.4. Business Strategy
      • 6.12.5. Recent Development
    • 6.13. Sanofi
      • 6.13.1. Overview
      • 6.13.2. Financials
      • 6.13.3. Product Portfolio
      • 6.13.4. Business Strategy
      • 6.13.5. Recent Development
    • 6.14. Boehringer Ingelheim GmbH
      • 6.14.1. Overview
      • 6.14.2. Financials
      • 6.14.3. Product Portfolio
      • 6.14.4. Business Strategy
      • 6.14.5. Recent Development

Table Of Figures

List of Figures

1. Market research process
2. Market research methodology
3. Global Breakthrough Therapy (BT) Designation Market , 2015–2025 (USD Billion)
4. Porter’s Five Forces Analysis
5. Global Breakthrough Therapy (BT) Designation Market attractiveness, By Application 
6.  Global Breakthrough Therapy (BT) Designation Market Share by Application ,2018 and 2025 (USD Billion)
7. Global Breakthrough Therapy (BT) Designation Market by Oncology ,2015–2025 (USD Billion)
8. Global Breakthrough Therapy (BT) Designation Market by Rare Diseases ,2015–2025 (USD Billion)
9. Global Breakthrough Therapy (BT) Designation Market by Infectious Diseases,2015–2025 (USD Billion)
10. Global Breakthrough Therapy (BT) Designation Market by Pulmonary Diseases,2015–2025 (USD Billion)
11. Global Breakthrough Therapy (BT) Designation Market by Autoimmune Diseases,2015–2025 (USD Billion)
12. Global Breakthrough Therapy (BT) Designation Market by Neurological Disorders,2015–2025 (USD Billion)
13. Global Breakthrough Therapy (BT) Designation Market by Others,2015–2025 (USD Billion)
14. Global Breakthrough Therapy (BT) Designation Market share, by Region, 2018 and 2025
15. North America Breakthrough Therapy (BT) Designation Market , 2015–2025 (USD Billion)
16. Europe Breakthrough Therapy (BT) Designation Market , 2015–2025 (USD Billion)
17. Asia Pacific Breakthrough Therapy (BT) Designation Market , 2015–2025 (USD Billion)
18. Latin America Breakthrough Therapy (BT) Designation Market , 2015–2025 (USD Billion)
19. The Middle East and Africa Breakthrough Therapy (BT) Designation Market , 2015–2025 (USD Billion)


Table Of Tables

List of Tables

1. Global Breakthrough Therapy (BT) Designation Market : snapshot
2. Drivers of the Breakthrough Therapy (BT) Designation Market : impact analysis
3. North America Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
4. The U.S. Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
5. Rest of North America Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
6. Europe Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
7. UK Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
8. France Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
9. Germany Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
10. Rest of Europe Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
11. Asia Pacific Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
12. China Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
13. Japan Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
14. India Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
15. Rest of Asia Pacific Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
16. Latin America Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
17. Brazil Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
18. Rest of Latin America Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
19. The Middle East and Africa Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
20. Saudi Arabia Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
21. South Africa Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)
22. Rest of the Middle East & Africa Breakthrough Therapy (BT) Designation Market revenue, By Application , 2015–2025 (USD Billion)


 
 

Methodology

FrequentlyAsked Questions

Inflating consumption of orphan medicines and large-scale acceptance of BT status in drugs will embellish the market expansion over the years ahead. Need for providing effective drug treatment to patients suffering from life-threatening ailments and necessity of bringing improvement in disease condition through determining of effective drug therapies will boost the market trends. In addition to this, surge in the healthcare spending in both emerging economies and developed countries will prompt the market size over the forecast timeline.

According to a report from Zion Market Research, the global Breakthrough Therapy (BT) Designation Market was valued at USD 130.78 Billion in 2023 and is projected to hit USD 529.08 Billion by 2032, with a compound annual growth rate (CAGR) of 16.8% during the forecast period 2024-2032

North America is likely to make noteworthy contributions towards overall market revenue. The regional market growth over 2019-2025 can be credited to favorable intellectual property legislations rewarding breakthroughs through data protection and copyright security. In addition to this, easy access to advanced healthcare facilities and surge in the chronic disorders will promulgate the market penetration over the forthcoming years. 

The key players profiled in the report include Regeneron; Boehringer Ingelheim GmbH; AbbVie, Inc.; GlaxoSmithKline plc; F. Hoffmann-La Roche Ltd; Sanofi; Novartis AG; Bristol-Myers Squibb Company; Amgen, Inc.; Acadia Pharmaceuticals, Inc.; Pfizer, Inc.; AstraZeneca; Gilead; Janssen Global Services, LLC; and Eli Lilly and Company.

Choose License Type

  • zion payment modes

List of Contents

Market InsightsMarket:OverviewMarket?: Growth DriversReport ScopeMarket:Regional InsightsNorth America To Establish Dominant Position In Global Market By 2032Competitive SpaceThe global breakthrough therapy (BT) designation market is segmented as follows:By Region

RelatedNews

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

twitter

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

How it Works?

Our Company

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed